Cyclacel
Investors & Media

News

All Releases
View Summary Cyclacel Pharmaceuticals to Release First Quarter 2016 Financial Results
May 4, 2016
PDF 13.9 KB Add to Briefcase
View Summary Cyclacel's Second-Generation CDK2/9 Inhibitor, CYC065, is an Effective Inducer of Cell Death in B-cell Lymphoma and Synergizes With Bcl-2 or BET Inhibitors
Apr 18, 2016
PDF 285.3 KB Add to Briefcase
View Summary Cyclacel Announces Receipt of Nasdaq Extension
Apr 11, 2016
PDF 13.5 KB Add to Briefcase
View Summary Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2015 Financial Results
Mar 24, 2016
PDF 31.3 KB Add to Briefcase
View Summary Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2015 Financial Results
Mar 17, 2016
PDF 13.4 KB Add to Briefcase
View Summary Cyclacel Announces Receipt of Nasdaq Staff Determination; Company to Request Hearing
Feb 5, 2016
PDF 13.0 KB Add to Briefcase
View Summary Cyclacel Pharmaceuticals to Present at the 18th Annual BIO CEO & Investor Conference
Feb 2, 2016
PDF 13.1 KB Add to Briefcase
View Summary Cyclacel Reviews 2015 Achievements and Announces Key Business Objectives for 2016
Jan 11, 2016
PDF 20.9 KB Add to Briefcase
View Summary Molecular Basis For Development of Cyclacel's CYC065 CDK2/9 Inhibitor In Triple-Negative Breast Cancer Presented At San Antonio Breast Cancer Symposium
Dec 14, 2015
PDF 15.1 KB Add to Briefcase
View Summary CYC065, Cyclacel's Novel CDK2/9 Inhibitor, Prolongs Survival in MYCN-Addicted Neuroblastoma Models
Nov 23, 2015
PDF 56.3 KB Add to Briefcase
View Summary Cyclacel Pharmaceuticals Reports Third Quarter 2015 Financial Results
Nov 12, 2015
PDF 29.1 KB Add to Briefcase
View Summary Mechanistic Rationale for CYC065, Cyclacel's CDK2/9 Inhibitor, in Targeted Solid Tumors and Hematological Malignancies Presented at AACR-NCI-EORTC International Conference
Nov 9, 2015
PDF 14.5 KB Add to Briefcase
View Summary Cyclacel Pharmaceuticals to Release Third Quarter 2015 Financial Results
Nov 5, 2015
PDF 12.5 KB Add to Briefcase
View Summary Data to be Presented on CYC065, Cyclacel's CDK2/9 Inhibitor, at AACR-NCI-EORTC International Conference
Oct 26, 2015
PDF 13.6 KB Add to Briefcase
View Summary Cyclacel Doses First Patient in Phase 1 Trial of Its Novel CDK2/9 Inhibitor, CYC065, for the Treatment of Advanced Solid Tumors
Oct 22, 2015
PDF 16.1 KB Add to Briefcase
View Summary Cyclacel Presents Molecular Rationale for Clinical Development of CYC065 CDK Inhibitor in Leukemias and Lymphomas
Sep 17, 2015
PDF 14.7 KB Add to Briefcase
View Summary Cyclacel Pharmaceuticals to Present at Rodman & Renshaw 17th Annual Global Investment Conference
Sep 3, 2015
PDF 11.0 KB Add to Briefcase
View Summary Cyclacel Pharmaceuticals Reports Second Quarter 2015 Financial Results
Aug 11, 2015
PDF 25.7 KB Add to Briefcase
View Summary Cyclacel Pharmaceuticals to Release Second Quarter 2015 Financial Results
Aug 5, 2015
PDF 13.4 KB Add to Briefcase
View Summary First Patient Dosed in IST of CDK Inhibitor Seliciclib in Cushing's Disease, a Serious Endocrine Disorder
Jul 2, 2015
PDF 16.0 KB Add to Briefcase
Showing 21-40 of 342 Page: 1 2 3 4 5 6 ... 18  Previous 20 | Next 20
Add to Briefcase = add release to Briefcase
Investors & Media